September 26, 2017
By Reiji Anasako The pharma industry has seen floundering sales of sodium-glucose co-transporter-2 (SGLT-2) inhibitors in Japan ever since their launch a few years ago. Now with recent statistics based on a national insurance claim database, dubbed NDB, it was...read more